Haemonetics stock heads into November 5 results with key benchmarks

Published on 10/05/2026 at 11:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Haemonetics stock heads toward November 5 results after fiscal Q1 revenue reached USD 339.38 million. The October 2 close was USD 104.68.

HAE, US4050241003, Illustration mit AI erstellt.

Haemonetics Corporation (ISIN US4050241003) closed at USD 104.68 on the NYSE on October 2, 2026, gaining 0.30 percent as the medical technology company approaches its next results date. ScanX reports that Haemonetics plans to publish fiscal Q2 2027 results on November 5, 2026, at 6:00 a.m. ET, followed by an investor call at 8:00 a.m. ET.

Revenue beats consensus in Q1

The upcoming report follows fiscal Q1 2027 revenue of USD 339.38 million for the quarter ended June 27, 2026. Markets Insider said that figure compared with USD 321.39 million in the year-earlier quarter, while net income was USD 33.01 million versus USD 34.03 million.

MarketBeat reported fiscal Q1 adjusted EPS of USD 1.14, above the USD 1.08 consensus estimate. Revenue also exceeded the USD 327.86 million consensus estimate, giving the November update two measurable benchmarks.

Analysts see mixed valuation signals

MarketBeat described the analyst consensus on October 2, 2026, as Moderate Buy, based on 11 brokerages with six Buy ratings, four Holds and one Strong Buy. The average 12-month price target was USD 99.78, below the October 2 close of USD 104.68.

Individual views remain more constructive in some cases. MarketBeat said Raymond James raised its price objective from USD 105.00 to USD 125.00 on September 3, 2026, while Barrington raised its target from USD 95.00 to USD 118.00 on August 19, 2026. The spread between the average target and the share price makes the November guidance update important for valuation.

Stock remains below its yearly high

Haemonetics traded between USD 103.61 and USD 105.70 on October 2, 2026, with volume of 328,574 shares. The 52-week range was USD 48.17 to USD 110.45, placing the close USD 5.77 below the yearly high.

Market capitalization stood at USD 4.8 billion as of October 2, 2026. For investors, the next concrete checkpoint is whether fiscal Q2 results confirm the revenue and adjusted EPS momentum shown in the quarter ended June 27.